Gain Therapeutics Inc. (GANX) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Gain Therapeutics Inc., updated every trading day.
Health Care · Biotechnology: Pharmaceutical Preparations
Price
$1.20
+2.14% today
Market cap
$51M
Overall quality
43/100
Kronos AI 30-day
+62.0%
8 of 8 simulated paths end higher
Gain Therapeutics Inc. (GANX) is a Health Care company in Biotechnology: Pharmaceutical Preparations, worth $51M. It trades at $1.20, up 2.14% today. Its overall quality score is 43 out of 100, ranked against the whole US market. 4 analysts' average target of $7.20 implies +500.0% from today's price. Kronos AI's 30-day forecast is +62.0% (8 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $7.20 |
| Low – high | $5.00 – $8.00 |
| Analysts | 4 |
| Upside to average | +500.0% |
Kronos AI 30-day forecast
| Expected close | $1.90 (+62.0%) |
| Likely range | +49.9% … +66.3% |
| As of | 2026-10-27 |
8 of 8 simulated paths end higher.
Quality scores
| Profitability | 35 |
| Solvency | 53 |
| Growth | 41 |
| Overall | 43 |
| P/E | — |
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: Pharmaceutical Preparations
For information only, not investment advice. Prices updated: 2026-10-29.